The company has announced that its new investigational device exemption will be used to launch a pivotal trial of its ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Background: Platelet activation plays a key role in peripheral artery disease (PAD), but the relevant platelet activation mechanism in chronic limb threatening ischemia remains unclear. Moreover, ...

Philips has now developed a device intended to integrate two forms of laser-based PAD therapy, atherectomy and intravascular ...

Peripheral artery disease (PAD) is a progressive atherosclerotic disease that causes lower extremity arterial stenosis or occlusion. Patients with PAD are at increased risk of myocardial infarction, ...

With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single ...

"The underpinnings of the relationship between peripheral vascular disease and atopic dermatitis ... and appropriate treatment of cardiovascular risk factors in this population," Cohen said.

PAD reduces quality of life because of physical limitations, pain, and psychological distress, necessitating multidisciplinary approaches involving rehabilitation, medication, and psychological ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

Diabetes Care. 2016. U.S. Centers for Disease Control and Prevention. About Peripheral Artery Disease. National Heart, Lung, and Blood Institute. Peripheral Artery Disease Treatment. Zemaitis MR, Boll ...

Within 24 h before the examination, the examinee refrained from using vasoactive drugs, avoided strenuous activities ... This pattern is consistent with the results of a study involving 103 patients ...

Following a greenlight from the US FDA, Philips has enrolled the first patient in a trial of its newest intravascular ...